Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 23;8(1):106-107.
doi: 10.1016/j.jacbts.2022.12.002. eCollection 2023 Jan.

Will Gene Editing Orphanize Rare Diseases?

Douglas L Mann
Editorial

Will Gene Editing Orphanize Rare Diseases?

Douglas L Mann. JACC Basic Transl Sci. .
No abstract available

PubMed Disclaimer

References

    1. Gillmore J.D., Taubel J., Gane E., et al. First-in-human in vivo CRISPR/Cas9 editing of the TTR Gene by NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy. AHA 2022 Presentation Slides. American College of Cardiology. https://www.acc.org/education-and-meetings/image-and-slide-gallery/media...
    1. Gene therapies should be for all. Nat Med. 2021;27:1311. doi: 10.1038/s41591-021-01481-9. - DOI - PubMed
    1. Urnov F. We can cure disease by editing a person’s DNA. Why aren’t we? New York Times. https://www.nytimes.com/2022/12/09/opinion/crispr-gene-editing-cures.html
    1. Heart Protection Study Collaborative Group Statin cost-effectiveness in the united states for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2:65–72. doi: 10.1161/CIRCOUTCOMES.108.808469. - DOI - PubMed
    1. Desai N.R., Campbell C., Electricwala B., et al. Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis. Am J Cardiovasc Drugs. 2022;22:545–556. doi: 10.1007/s40256-022-00534-9. - DOI - PMC - PubMed

Publication types

LinkOut - more resources